Subscribe To
URGN / UroGen Pharma: Jelmyto Sales Growing Steadily, Concerns Remain
URGN News
By Zacks Investment Research
August 18, 2023
UroGen Pharma (URGN) Stock Surges 89% in a Month: Here's Why
This jump in UroGen's (URGN) stock price is attributable to positive data from two late-stage studies on bladder cancer therapy. An FDA filing for the more_horizontal
By Zacks Investment Research
August 10, 2023
Wall Street Analysts Think Urogen Pharma (URGN) Could Surge 89.61%: Read This Before Placing a Bet
The consensus price target hints at an 89.6% upside potential for Urogen Pharma (URGN). While empirical research shows that this sought-after metric i more_horizontal
By The Motley Fool
July 28, 2023
Why Shares of UroGen Pharma Jumped Friday
UroGen also announced a $120 million private placement to raise funds. The company said it could have its second marketed product as early as next yea more_horizontal
By Zacks Investment Research
March 16, 2023
Urogen Pharma (URGN) Reports Q4 Loss, Lags Revenue Estimates
Urogen Pharma (URGN) delivered earnings and revenue surprises of -8.93% and 0.87%, respectively, for the quarter ended December 2022. Do the numbers h more_horizontal
By Seeking Alpha
February 8, 2023
UroGen: Struggling With Revenue And With Cash Runway
UroGen has an approved drug and a platform. However, there's not much growth in revenue. more_horizontal
By Seeking Alpha
November 21, 2022
UroGen Pharma: Jelmyto Sales Growing Steadily, Concerns Remain
Shares have lost nearly two-thirds of their value over the past 3 years. RTGel platform is a great fit for bladder cancers due to its ability to allow more_horizontal
By Seeking Alpha
November 10, 2022
UroGen Pharma Ltd. (URGN) Q3 2022 Earnings Call Transcript
UroGen Pharma Ltd. (NASDAQ:URGN ) Q3 2022 Earnings Conference Call November 10, 2022 10:00 AM ET Company Participants Vincent Perrone - Senior Directo more_horizontal
By Seeking Alpha
August 11, 2022
Urogen Pharma Ltd (URGN) CEO Elizabeth Barrett on Q2 2022 Results - Earnings Call Transcript
Urogen Pharma Ltd (NASDAQ:URGN ) Q2 2022 Earnings Conference Call August 11, 2022 10:00 AM ET Company Participants Vincent Perrone - Senior Director, more_horizontal